328 related articles for article (PubMed ID: 12101432)
1. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors.
Beaty RM; Jackson M; Peterson D; Bird A; Brown T; Benjamin DK; Juopperi T; Kishnani P; Boney A; Chen YT; Koeberl DD
Gene Ther; 2002 Aug; 9(15):1015-22. PubMed ID: 12101432
[TBL] [Abstract][Full Text] [Related]
2. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
3. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
4. Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia.
Crane B; Luo X; Demaster A; Williams KD; Kozink DM; Zhang P; Brown TT; Pinto CR; Oka K; Sun F; Jackson MW; Chan L; Koeberl DD
Gene Ther; 2012 Apr; 19(4):443-52. PubMed ID: 21654821
[TBL] [Abstract][Full Text] [Related]
5. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
[TBL] [Abstract][Full Text] [Related]
7. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
[TBL] [Abstract][Full Text] [Related]
10. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
11. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
[TBL] [Abstract][Full Text] [Related]
12. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
[TBL] [Abstract][Full Text] [Related]
13. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
15. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
16. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
[TBL] [Abstract][Full Text] [Related]
17. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
18. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
Müller OJ; Leuchs B; Pleger ST; Grimm D; Franz WM; Katus HA; Kleinschmidt JA
Cardiovasc Res; 2006 Apr; 70(1):70-8. PubMed ID: 16448634
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Lin CY; Ho CH; Hsieh YH; Kikuchi T
Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
[TBL] [Abstract][Full Text] [Related]
20. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
